Hypoimmune iPSC-Derived Corneal Cells: Establishing and validating three novel cell types (iCE, iCS, and iCEn) that enhance graft acceptance and reduce immune rejection.

Advanced Clinical-Grade Bioinks: Developing cell-specific bioinks engineered for optimal integration with host tissues, improving graft stability and reducing failure rates.

Novel Corneal Holder Technology: Utilising Melt Electrowriting (MEW) printing to create an innovative corneal holder that supports cell-laden bioprinted corneal grafts and enables secure suturing.

Innovative packaging and logistics solutions: Developing packaging and shipment solutions, essential for preserving the structural integrity of the bioprinted corneal grafts, thereby ensuring their successful implantation.

These pioneering components will be integrated into a state-of-the-art 3D bioprinter with a Laser-Assisted Bioprinting (LaBP) unit capable of producing full-thickness corneal grafts in under two hours. The resulting grafts will replicate the native human cornea's mechanical and optical properties, ensuring high-performance outcomes.